期刊文献+

设计类固醇兴奋剂的特征分析及发展预测 被引量:1

Feature Analysis and Future Perspective of Designer Steroid
下载PDF
导出
摘要 目的:针对设计类固醇兴奋剂,分析并探讨其设计特点和发展趋势。方法:文献资料法和理论分析法。结论:设计类固醇兴奋剂是一些没有纳入世界反兴奋剂条例禁用物质清单的类固醇药物,或者是利用兴奋剂检测方法存在的不足为逃脱药检而专门设计的类固醇药物,其未来的主要趋势是制造现今例行的运动兴奋剂控制尿样筛选、检测中容易分解的类固醇兴奋剂;另一个重要的趋势是从现有商品流通渠道和世界反兴奋剂条例禁用物质清单之外寻找或直接开发合成代谢活性高的合成类固醇药物。 Objective:Investigate the characteristic of designer steroid and discuss its development directions. Methods: Literature review and theoretical analysis. Conclusion: The primaryorientation in designer steroid research is to find novel designer steroid undeteetable in present routine sports doping control tests,another major direction is to search in exist steroid for ones with high anabolie activity but neither marketed nor named on the prohibited list at present, or to find new ones.
作者 袁飚
出处 《天津体育学院学报》 CAS CSSCI 北大核心 2007年第5期422-425,共4页 Journal of Tianjin University of Sport
  • 相关文献

参考文献38

  • 1Michael H Sekera,Brian D Ahrens,Yu-Chen Chang,et al.Another designer steroid:discovery,synthesis,and detection of ' madol ' in urine[J].Rapid Commun Mass Spectrom,2005,19:781-784.
  • 2Buzby G C,Walk C R,Smith H[J].J.Med.Chem,1966,9:782.
  • 3吴侔天,王杉,王小兵.世界反兴奋剂条例2005年禁用清单[EB/OL].http://news.sports.cn/incitant/2005table.doc,2005-01-12.
  • 4Catlin D H,Leder B Z,Ahrens B,et al[J].JS.Steroids,2002,67:400.
  • 5Don H Catlin,Brian D Ahrens,Yulia Kucherova.Detection of norbolethone,an anabolic steroid never marketed,in athletes' urine[J].Rapid Commun.Mass Spectrom,2002,16:1 273-1 275.
  • 6David J Handelsman.Designer androgens in sport:when too much is never enough[J].Sci STKE,2004:pe41.
  • 7吴熙瑞.避孕药临床应用40年回顾与展望[J].中国实用妇科与产科杂志,2005,21(1):1-4. 被引量:22
  • 8国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2005.114.
  • 9Mario Thevis,Ute Bommerich,Georg Opfermann,et al.Characterization of chemically modified steroids for doping control purposes by electrospray ionization tandem mass spectrometry[J].J.Mass Spectrom,2005,40:494-502.
  • 10Gogate A N[J].J.Med.Chem,1969,23:648.

二级参考文献20

  • 1WHO RHR. Selected practice recommendations for contraceptive use 2002 World Health Organiation. Improving access to quality care in family planning. Medical eligibility criteria for contraceptiv use. 2nd ed. 2000 World Health Organization.
  • 2WHO. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive urn. 3rd ed. [ 2004 - 04 - 02 ].http: www. WHO. Int/reproductive-health/publications/MEC-3/change-tables. html.
  • 3WHO RHR. Contraceptive implants come of age. Prog Reprod Health Res, 2003,61 ~ 1.
  • 4Sivin I, Croxatto H, Bahamondes L, et al. Two-year perfomaance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception,2004,69(2) : 137-143.
  • 5Dieben TO,Roumen FJ,Apter D. Efficacy,cycle control,and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol, 2002,100 (3) : 585-591.
  • 6Audet MC, Moreau M, Koltum WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptivepatch vs. an oral contraceptive: a randomized controlled trial. JAMA, 2001,285(18) :2347-2351.
  • 7Loose-Mitchell DS, Stancel GM. Estrogens and progestins in Goodman and Gilman's. The Pharmacolgical Basis of Therapeutic, 2002. 1579.
  • 8Edwarcks KG, Cohen J. Reproductive choice in 2002 : the relative safety of current oral contraceptives. Hum Reprod Experts, 2000,1:1.
  • 9WHO. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 2nd ed. 2000 World Health Organization.
  • 10MacBeath G, Schreiber S L. Printing proteins as microarrays for high-throughput function determination. Science, 2000, 289(5485):1760.

共引文献764

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部